Literature DB >> 24642454

Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se.

Andrew J Hill1, Nicholas A Jones1, Imogen Smith2, Charlotte L Hill1, Claire M Williams3, Gary J Stephens2, Benjamin J Whalley4.   

Abstract

Cannabidiol (CBD) is a non-psychoactive, well-tolerated, anticonvulsant plant cannabinoid, although its mechanism(s) of seizure suppression remains unknown. Here, we investigate the effect of CBD and the structurally similar cannabinoid, cannabigerol (CBG), on voltage-gated Na(+) (NaV) channels, a common anti-epileptic drug target. CBG's anticonvulsant potential was also assessed in vivo. CBD effects on NaV channels were investigated using patch-clamp recordings from rat CA1 hippocampal neurons in brain slices, human SH-SY5Y (neuroblastoma) cells and mouse cortical neurons in culture. CBG effects were also assessed in SH-SY5Y cells and mouse cortical neurons. CBD and CBG effects on veratridine-stimulated human recombinant NaV1.1, 1.2 or 1.5 channels were assessed using a membrane potential-sensitive fluorescent dye high-throughput assay. The effect of CBG on pentyleneterazole-induced (PTZ) seizures was assessed in rat. CBD (10μM) blocked NaV currents in SH-SY5Y cells, mouse cortical neurons and recombinant cell lines, and affected spike parameters in rat CA1 neurons; CBD also significantly decreased membrane resistance. CBG blocked NaV to a similar degree to CBD in both SH-SY5Y and mouse recordings, but had no effect (50-200mg/kg) on PTZ-induced seizures in rat. CBD and CBG are NaV channel blockers at micromolar concentrations in human and murine neurons and recombinant cells. In contrast to previous reports investigating CBD, CBG had no effect upon PTZ-induced seizures in rat, indicating that NaV blockade per se does not correlate with anticonvulsant effects.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anticonvulsant; Cannabinoid; Dravet syndrome; Epilepsy; Seizure; Sodium channels

Mesh:

Substances:

Year:  2014        PMID: 24642454     DOI: 10.1016/j.neulet.2014.03.013

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  27 in total

1.  Veratridine modifies the gating of human voltage-gated sodium channel Nav1.7.

Authors:  Xiao-Yu Zhang; Rui-Yun Bi; Peng Zhang; Ye-Hua Gan
Journal:  Acta Pharmacol Sin       Date:  2018-06-27       Impact factor: 6.150

Review 2.  Endothelial atypical cannabinoid receptor: do we have enough evidence?

Authors:  Alexander I Bondarenko
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

3.  Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).

Authors:  Brian D Klein; Catherine A Jacobson; Cameron S Metcalf; Misty D Smith; Karen S Wilcox; Aidan J Hampson; John H Kehne
Journal:  Neurochem Res       Date:  2017-05-06       Impact factor: 3.996

Review 4.  Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.

Authors:  Gareth Pryce; Dieter R Riddall; David L Selwood; Gavin Giovannoni; David Baker
Journal:  J Neuroimmune Pharmacol       Date:  2014-12-24       Impact factor: 4.147

Review 5.  Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities.

Authors:  Dinesh Upadhya; Olagide W Castro; Raghavendra Upadhya; Ashok K Shetty
Journal:  Mol Neurobiol       Date:  2018-01-25       Impact factor: 5.590

Review 6.  Development of cannabidiol as a treatment for severe childhood epilepsies.

Authors:  Claire M Williams; Gary J Stephens
Journal:  Br J Pharmacol       Date:  2020-10-27       Impact factor: 8.739

7.  Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol.

Authors:  Reesha R Patel; Cindy Barbosa; Tatiana Brustovetsky; Nickolay Brustovetsky; Theodore R Cummins
Journal:  Brain       Date:  2016-06-05       Impact factor: 13.501

Review 8.  Molecular Targets of Cannabidiol in Neurological Disorders.

Authors:  Clementino Ibeas Bih; Tong Chen; Alistair V W Nunn; Michaël Bazelot; Mark Dallas; Benjamin J Whalley
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

9.  Modulation of Recombinant Human T-Type Calcium Channels by Δ9-Tetrahydrocannabinolic Acid In Vitro.

Authors:  Somayeh Mirlohi; Chris Bladen; Marina Santiago; Mark Connor
Journal:  Cannabis Cannabinoid Res       Date:  2021-01-21

10.  Cannabidiol Inhibition of Murine Primary Nociceptors: Tight Binding to Slow Inactivated States of Nav1.8 Channels.

Authors:  Han-Xiong Bear Zhang; Bruce P Bean
Journal:  J Neurosci       Date:  2021-06-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.